Trials / Completed
CompletedNCT00191373
A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease
Phase II Study of Gemcitabine and Trastuzumab Therapy in Patients With HER2 Overexpressing Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (planned)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase II trial that includes Gemcitabine 1,250mg/m2 to be administered over approximately 30 minutes on days 1 and 8, every 21 days and Trastuzumab 8 mg/kg IV to be administered over 90 minutes on day 1 of the first cycle, then 6mg/kg as a 30 minute infusion administered on subsequent cycles.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemcitabine | |
| DRUG | Trastuzumab |
Timeline
- Start date
- 2002-03-01
- Completion
- 2007-07-01
- First posted
- 2005-09-19
- Last updated
- 2007-09-12
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00191373. Inclusion in this directory is not an endorsement.